Literature DB >> 27120700

Successful implementation of outpatient parenteral antimicrobial therapy at a medical respite facility for homeless patients.

Alison M Beieler1, Timothy H Dellit1,2, Jeannie D Chan1,3, Shireesha Dhanireddy1,2, Leslie K Enzian4, Tamera J Stone4, Edward Dwyer-O'Connor4, John B Lynch1,2.   

Abstract

BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) is a safe way to administer intravenous (IV) antimicrobial therapy to patients with the potential to decrease hospital length of stay (LOS). Often, homeless patients with complex infections, who could otherwise be treated as an outpatient, remain in the hospital for the duration of IV antibiotic treatment. Injection drug use (IDU) is a barrier to OPAT.
OBJECTIVE: To evaluate our experience with administering OPAT to homeless patients at a medical respite facility and determine if patients could complete a successful course of antibiotics.
DESIGN: Using retrospective chart review, demographics, diagnosis, and comorbidities including mental illness, current IDU, and remote IDU (>3 months ago) were recorded. Surgical, microbiologic, and antimicrobial therapy including route (IV or oral), duration of therapy, and adverse events were abstracted. PARTICIPANTS: Homeless patients >18 years old who received OPAT at medical respite after discharge, no exclusions. MAIN MEASUREMENTS: Primary outcome was successful completion of OPAT at medical respite. Secondary outcome was successful antimicrobial course completion for a specific diagnosis.
RESULTS: Forty-six (87%) patients successfully completed a defined course of antibiotic therapy. Thirty-four (64%) patients were successfully treated with OPAT at medical respite. Readmission rate was 30%. The average length of OPAT was 22 days. The cost savings to our institution (using $1500/day inpatient cost) was $25,000 per episode of OPAT.
CONCLUSIONS: OPAT can be successful in a supervised medical respite setting for homeless patients with the help of a multidisciplinary team, and can decrease inpatient LOS resulting in cost savings. Journal of Hospital Medicine 2016;11:531-535.
© 2016 Society of Hospital Medicine. © 2016 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27120700     DOI: 10.1002/jhm.2597

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  12 in total

1.  Lessons learned from the implementation of a medically enhanced residential treatment (MERT) model integrating intravenous antibiotics and residential addiction treatment.

Authors:  Honora Englander; Talitha Wilson; Devin Collins; Elena Phoutrides; Melissa Weimer; P Todd Korthuis; Jessica Calcagni; Christina Nicolaidis
Journal:  Subst Abus       Date:  2018       Impact factor: 3.716

2.  Outpatient Parenteral Antimicrobial Therapy in Vulnerable Populations-- People Who Inject Drugs and the Homeless.

Authors:  Alison Beieler; Amalia Magaret; Yuan Zhou; Anneliese Schleyer; Anna Wald; Shireesha Dhanireddy
Journal:  J Hosp Med       Date:  2019-02       Impact factor: 2.960

3.  Feasibility and Safety of Outpatient Parenteral Antimicrobial Therapy in Conjunction With Addiction Treatment for People Who Inject Drugs.

Authors:  Christin N Price; Daniel A Solomon; Jennifer A Johnson; Mary W Montgomery; Bianca Martin; Joji Suzuki
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

4.  Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy.

Authors:  Sara C Keller; Deborah Williams; Mitra Gavgani; David Hirsch; John Adamovich; Dawn Hohl; Ayse P Gurses; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

5.  Estimating and Evaluating Tuberculosis Incidence Rates Among People Experiencing Homelessness, United States, 2007-2016.

Authors:  Julie L Self; Clint J McDaniel; Sapna Bamrah Morris; Benjamin J Silk
Journal:  Med Care       Date:  2021-04-01       Impact factor: 3.178

Review 6.  Outpatient Parenteral Antimicrobial Therapy Among People Who Inject Drugs: A Review of the Literature.

Authors:  Joji Suzuki; Jennifer Johnson; Mary Montgomery; Margaret Hayden; Christin Price
Journal:  Open Forum Infect Dis       Date:  2018-08-07       Impact factor: 3.835

7.  Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population.

Authors:  Chloe Bryson-Cahn; Alison M Beieler; Jeannie D Chan; Robert D Harrington; Shireesha Dhanireddy
Journal:  Open Forum Infect Dis       Date:  2019-01-30       Impact factor: 3.835

Review 8.  Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.

Authors:  Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton
Journal:  JAC Antimicrob Resist       Date:  2019-08-26

9.  A Novel Program to Provide Drug Recovery Assistance and Outpatient Parenteral Antibiotic Therapy in People Who Inject Drugs.

Authors:  Stephanie S Gelman; Eddie Stenehjem; Rachel A Foster; Nick Tinker; Nancy Grisel; Brandon J Webb
Journal:  Open Forum Infect Dis       Date:  2021-12-10       Impact factor: 3.835

10.  Evaluating the safety and effectiveness of a nurse-led outpatient virtual IV vancomycin monitoring clinic: a retrospective cohort study.

Authors:  Kate S Grattan; Mohamed Mohamed Ali; Seyed M Hosseini-Moghaddam; Hayley J I Gilmour; Gregory P Crunican; Erica Hua; Kelly A Muhsin; Rochelle Johnstone; Lise C Bondy; Megan K Devlin; Sarah Shalhoub; Sameer Elsayed; Michael S Silverman
Journal:  JAC Antimicrob Resist       Date:  2021-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.